Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12,506 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Understanding effect site pharmacology of uprifosbuvir, a hepatitis C virus nucleoside inhibitor: Case study of a multidisciplinary modeling approach in drug development.
van den Berg P, Gao W, Ahsman MJ, Arrington L, Kesisoglou F, Miller R, Post TM, Rizk ML. van den Berg P, et al. Among authors: gao w. CPT Pharmacometrics Syst Pharmacol. 2021 Jul;10(7):658-670. doi: 10.1002/psp4.12644. Epub 2021 Jun 18. CPT Pharmacometrics Syst Pharmacol. 2021. PMID: 33934558 Free PMC article.
Efficacy and safety of ruzasvir 60 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4 or 6 infection.
Lawitz E, Poordad F, Anderson LJ, Vesay M, Kelly MM, Liu H, Gao W, Fernsler D, Asante-Appiah E, Robertson MN, Hanna GJ, Barr E, Butterton J, Kowdley KV, Hassanein T, Sahota A, Gordon SC, Yeh WW. Lawitz E, et al. Among authors: gao w. J Viral Hepat. 2019 Jun;26(6):675-684. doi: 10.1111/jvh.13079. Epub 2019 Mar 12. J Viral Hepat. 2019. PMID: 30739366 Clinical Trial.
Population pharmacokinetics of molnupiravir in adults with COVID-19: Lack of clinically important exposure variation across individuals.
Bihorel S, Cao Y, Chawla A, Birger R, Maas BM, Gao W, Roepcke S, Sardella S, Humphrey R, Kondragunta S, Jayaraman B, Martinho M, Painter W, Painter G, Holman W, De Anda C, Brown ML, Johnson MG, Paschke A, Rizk ML, Stone JA. Bihorel S, et al. Among authors: gao w. CPT Pharmacometrics Syst Pharmacol. 2023 Dec;12(12):1859-1871. doi: 10.1002/psp4.13031. Epub 2023 Oct 5. CPT Pharmacometrics Syst Pharmacol. 2023. PMID: 37798914 Free PMC article. Clinical Trial.
Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label trials.
Lawitz E, Buti M, Vierling JM, Almasio PL, Bruno S, Ruane PJ, Hassanein TI, Muellhaupt B, Pearlman B, Jancoriene L, Gao W, Huang HC, Shepherd A, Tannenbaum B, Fernsler D, Li JJ, Grandhi A, Liu H, Su FH, Wan S, Dutko FJ, Nguyen BT, Wahl J, Robertson MN, Barr E, Yeh WW, Plank RM, Butterton JR, Yoshida EM. Lawitz E, et al. Among authors: gao w. Lancet Gastroenterol Hepatol. 2017 Nov;2(11):814-823. doi: 10.1016/S2468-1253(17)30163-2. Epub 2017 Aug 10. Lancet Gastroenterol Hepatol. 2017. PMID: 28802814 Clinical Trial.
Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials.
Gane EJ, Pianko S, Roberts SK, Thompson AJ, Zeuzem S, Zuckerman E, Ben-Ari Z, Foster GR, Agarwal K, Laursen AL, Gerstoft J, Gao W, Huang HC, Fitzgerald B, Fernsler D, Li JJ, Grandhi A, Liu H, Su FH, Wan S, Zeng Z, Chen HL, Dutko FJ, Nguyen BT, Wahl J, Robertson MN, Barr E, Yeh WW, Plank RM, Butterton JR, Esteban R. Gane EJ, et al. Among authors: gao w. Lancet Gastroenterol Hepatol. 2017 Nov;2(11):805-813. doi: 10.1016/S2468-1253(17)30159-0. Epub 2017 Aug 10. Lancet Gastroenterol Hepatol. 2017. PMID: 28802816 Clinical Trial.
Probability of Target Attainment Analyses to Inform Ceftolozane/Tazobactam Dosing Regimens for Patients With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia and End-Stage Renal Disease Receiving Intermittent Hemodialysis.
Feng HP, Patel YT, Zhang Z, Fiedler-Kelly J, Bruno CJ, Rhee EG, De Anda C, Gao W. Feng HP, et al. Among authors: gao w. J Clin Pharmacol. 2023 Feb;63(2):166-171. doi: 10.1002/jcph.2149. Epub 2022 Oct 2. J Clin Pharmacol. 2023. PMID: 36046982 Free PMC article. Clinical Trial.
Outcomes in Participants with Renal Impairment from a Phase 3 Clinical Trial for Ceftolozane/Tazobactam Treatment of Nosocomial Pneumonia (ASPECT-NP).
Huntington JA, Yu B, Li L, Jensen E, Bruno C, Boakye M, Zhang Z, Gao W, Feng HP, Rhee E. Huntington JA, et al. Among authors: gao w. Antimicrob Agents Chemother. 2020 Nov 17;64(12):e00731-20. doi: 10.1128/AAC.00731-20. Print 2020 Nov 17. Antimicrob Agents Chemother. 2020. PMID: 32988827 Free PMC article. Clinical Trial.
Exposure-Efficacy Analyses Support Optimal Dosing Regimens of Ceftolozane/Tazobactam in Participants with Hospital-Acquired/Ventilator-Associated Bacterial Pneumonia in ASPECT-NP.
Gao W, Passarell J, Patel YT, Zhang Z, Lin G, Fiedler-Kelly J, Bruno CJ, Rhee EG, De Anda CS, Feng HP. Gao W, et al. Antimicrob Agents Chemother. 2022 May 17;66(5):e0139921. doi: 10.1128/aac.01399-21. Epub 2022 Apr 26. Antimicrob Agents Chemother. 2022. PMID: 35471040 Free PMC article. Clinical Trial.
12,506 results
You have reached the last available page of results. Please see the User Guide for more information.